E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult individuals with bipolar I disorders who initiate lithium treatment based on the decision of themselves and their clinician |
Patienten mit einer Bipolar-I-Störung bei denen Arzt und Patient die Entscheidung zum Beginn einer Lithium-Therapie getroffen haben |
|
E.1.1.1 | Medical condition in easily understood language |
Adult individuals with bipolar I disorders who initiate lithium treatment based on the decision of themselves and their clinician |
Patienten mit einer Bipolar-I-Störung bei denen Arzt und Patient die Entscheidung zum Beginn einer Lithium-Therapie getroffen haben |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057667 |
E.1.2 | Term | Bipolar disorder |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to identify the eligibility criteria for treatment with Li in BDI in terms of response, safety and tolerability
Primary Objective: To classify the participants according to different definitions of Lithium response |
Ziel der Studie ist es, prädiktive Faktoren für eine Lithiumtherapie von BDI-Patienten im Hinblick auf Ansprechen, Sicherheit und Verträglichkeit zu identifizieren Primäres Ziel der Prüfung: Klassifizierung der Patienten nach Ansprechen auf Lithium |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the prognostic values of the biomarkers collected during the first three months of Lithium treatment on long term Lithium response (2 years) |
Evaluation des prädiktiven Wertes von während der ersten drei Monate einer Lithiumbehandlung gesammelten Biomarkern im Hinblick auf das Langzeitansprechen (2 Jahre) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Decision to prescribe Li as a prophylactic treatment based on clinicians' assessment 2. Confirmed diagnosis of BD1 according to DSM-5 criteria [based on the Mood section of the SCID] 3. Aged 18-70 years. 4. Able and willing to give written informed consent
|
Entscheidung, eine Lithiumbehandlung zu beginnen vor Einschluss in die klinische Studie Diagnose einer bipolaren Störung BD1 gemäß DSM-5 Kriterien Teilnehmer/innen zwischen 18 und 70 Jahren schriftliche Einwilligung nach erfolgter Aufklärung
|
|
E.4 | Principal exclusion criteria |
1 Trial of Lithium undertaken within the last 6 months 2 Lifetime history of mood disorder better explained by a DSM-5 definition for schizoaffective disorder [based on the relevant section of the SCID] 3 Pre-lithium screening suggest that Lithium initiation is contraindicated: 4 Participation in another research protocol that interferes with the evaluation of Lithium response (efficacy or tolerance) 5 Severe risk of self-harm at present, based on clinician's evaluation 6 Protected adult |
Teilnahme an einer Studie mit Lithiumbehandlung innerhalb der letzten sechs Monate vor Beginn der Studie Schizoaffektive Störung gemäß DSM-5 Kriterien in der Vorgeschichte Anzeichen für eine Lithium-Kontraindikation im entsprechenden Screening: Teilnahme an einer anderen interventionellen klinischen Prüfung innerhalb der letzten vier Wochen Hohes Risiko der Selbstgefährdung nach Einschätzung des behandelnden Arztes Personen mit bestehender oder vorgesehener gesetzlicher Betreuung
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
After all study participants have completed the follow-up period, the expert panel will reach a consensus on the classification of each participant into one of three categories: (i) good responders (GR), (ii) partial responders (PR), (iii) non-responders (NR). If no clinical followup data are available, the participant will be categorized as unclassifiable (UC). |
Klassifizierung der Lithiumresponse aller Studienteilnehmer/innen nach Beendigung der Follow-up-Periode durch ein Expertengremium in eine der drei Kategorien (i) „good responders“ (GR), (ii) „partial responders“ (PR) oder (iii) „non-responders“ (NR) zuordnen. Wenn keine Followup-Daten vorliegen, wird der/die entsprechende Studienteilnehmer/in als „unclassifiable“ (UC) kategorisiert. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all study participants have completed the follow-up period |
wenn alle Studienteilnehmer die Followup-Periode beendet haben |
|
E.5.2 | Secondary end point(s) |
There are several possible definitions of treatment response that employ different levels of precision. a) - Response assessed retrospectively by estimating the total score on the Retrospective Longitudinal Evaluation of Lithium Response, also known as the "Alda" Scale - Comparison of the BDI illnesss activity for the two years pre-/post-Li Initiation ("mirror Image" design) b) Time dependent measures of Outcome - time to a new BD Episode (defined as Meeting DSM-5 diagnostic criteria after a period of euthymia (for a Minimum of 8 weeks) - time to a new hospitalisation for BD - time to prescription of a new mood stabilizer (either an adjunct or alternative to Lithium) c) Continuous ratings of BD symptoms |
a) Alda Scale Vergleich des BD I vor und nach 2 Jahren Lithiumeinnahme b) zeitabhänige Messungen des Ergebnisses - Zeitspanne bis zu einer neuen affektiven Episode(nach mind. 8 Wochen Euthymie) - Zeitspanne bis zu einer Hospitalisierung aufgrund einer neuen affektiven Episode - Zeitspanne bis zur Verordnung eines neuen Medikamentes zur Stimmungsstabilisierung c)Kontinuierliches Rating von BD-Symptomen
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
monthly visits (face to face or telephone) for 24 months |
monatliche Visiten (Vor Ort oder telefonisch) für 24 Monate |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS
|
Letzte Visite des letzten Patienten |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 48 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 48 |